Enzastaurin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous T-Cell Lymphoma

Conditions

Cutaneous T-Cell Lymphoma

Trial Timeline

Sep 1, 2008 → Feb 1, 2010

NCT ID

NCT00744991

About Enzastaurin

Enzastaurin is a phase 2 stage product being developed by Eli Lilly for Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00744991. Target conditions include Cutaneous T-Cell Lymphoma.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous T-Cell Lymphoma were approved

Approved (7) Terminated (1) Active (12)

✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved

✅ONTAKEisaiApproved

✅MogamulizumabKyowa KirinApproved

✅Clopidogrel + TicagrelorAstraZenecaApproved

✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved

✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01432951	Phase 1	Completed	Nov 1, 2011	Jan 5, 2018	Solid Tumor
NCT00744991	Phase 2	Completed	Sep 1, 2008	Feb 1, 2010	Cutaneous T-Cell Lymphoma
NCT00718419	Phase 2	Completed	Jul 1, 2008	Aug 1, 2012	Waldenstrom's Macroglobulinemia
NCT00542919	Phase 2	Completed	Nov 1, 2007	Feb 27, 2018	T-Cell Lymphoma
NCT00475644	Phase 2	Completed	May 1, 2007	Dec 1, 2014	Lymphoma, Follicular
NCT00452257	Phase 1	Completed	May 1, 2007	Sep 1, 2008	Leukemia, Lymphocytic
NCT00420381	Phase 2	Completed	Jan 1, 2007	Dec 1, 2014	Ovarian Cancer
NCT00428714	Phase 2	Completed	Jan 1, 2007	Jan 1, 2011	Prostate Cancer
NCT00309140	Phase 2	Completed	Mar 1, 2006	Jul 1, 2009	Neoplasms
NCT00088205	Phase 2	Completed	Mar 1, 2004	May 1, 2008	Mantle-Cell Lymphoma
NCT00190723	Phase 2	Completed	Oct 1, 2002	Dec 1, 2006	Malignant Glioma

Competing Products

20 competing products in Cutaneous T-Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	43
ONTAK	Eisai	Approved	43
E7777 9 mcg/kg	Eisai	Phase 3	40
ONTAK	Eisai	Approved	43
Mogamulizumab	Kyowa Kirin	Approved	47
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	36
Mogamulizumab	Kyowa Kirin	Phase 2	39
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	40
Clopidogrel + Ticagrelor	AstraZeneca	Approved	43
Pembrolizumab	Merck	Phase 2	42
Comparator: vorinostat	Merck	Pre-clinical	26
Pembrolizumab	Merck	Phase 2	39
TR701 FA	Merck	Phase 2	35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Tulisokibart + Placebo	Merck	Phase 2	39
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	35
Pembrolizumab + Mogamulizumab	Merck	Phase 2	42
TR-701 FA + Linezolid	Merck	Phase 3	40
Pimasertib + Dacarbazine	Merck	Phase 2	35